Bind launches second PhII trial for prostate cancer nanomed

Bind's Accurin technology entered the second Phase II trial in the form of its prostate cancer drug, BIND-014.--Courtesy of Bind

Bind Therapeutics, just after filing to go public last week, began dosing its first patient in the second of two Phase II trials of its nanoparticle prostate cancer drug BIND-014.

Bind, which sprang from the lab of MIT professor Robert Langer, specializes in the delivery of nanomedicines, particularly for difficult-to-treat forms of cancer. The company's technology, targeted and programmable nanoparticles called Accurins, is designed to carry the cancer drug docetaxel to prostate cancer that is resistant to chemotherapy. BIND-014 is the first of the company's Accurins to reach the clinic, having passed Phase I in April.

The 40-patient Phase II study is designed to determine the efficacy of BIND-014 in patients with chemotherapy-naïve metastatic castrate-resistant prostate cancer, according to the company. Among the platform's advances are prolonged circulation due to a protective layer, highly specific targeting with surface ligands designed to home in on cancer cells and a timely release controlled by the particle's polymeric matrix.

"While treatment options for metastatic castrate-resistant prostate cancer have advanced in recent years, primarily due to an increased understanding of androgen receptor biology, a significant unmet need remains for patients who fail hormonal agents," Bind Chief Medical Officer Dr. Gregory Berk said in a statement. "We are pleased our Phase I trial of BIND-014 established the safety profile and appropriate Phase II dose, and we are advancing BIND-014 in clinical development to further evaluate it as a potential option for patients who are in need of more effective therapies."

Just last week, the Cambridge, MA-based Bind filed with the U.S. Securities and Exchange Commission (SEC) to go public, aiming to raise a little more than $80 million. The company has some high-profile partners in Amgen ($AMGN), Pfizer ($PFE) and AstraZeneca ($AZN), as well as more than $1 billion in potential milestone agreements.

- here's the release